Peripherally targeted analgesia via AAV-mediated sensory neuron-specific inhibition of multiple pronociceptive sodium channels

Seung Min Shin, … , Quinn H. Hogan, Hongwei Yu

*J Clin Invest.* 2024. [https://doi.org/10.1172/JCI170813](https://doi.org/10.1172/JCI170813).

In-Press Preview

This study reports that targeting intrinsically disordered regions of Na\(_{\text{v}1.7}\) protein facilitates discovery of sodium channel inhibitory peptide aptamers (Na\(_{\text{v}}\)iPA) for adeno-associated virus (AAV)-mediated, sensory neuron-specific analgesia. A multipronged inhibition of \(I_{\text{Na}1.7}\), \(I_{\text{Na}1.6}\), \(I_{\text{Na}1.3}\), and \(I_{\text{Na}1.1}\) but not \(I_{\text{Na}1.5}\) and \(I_{\text{Na}1.8}\) was found for a prototype, named Na\(_{\text{v}}\)iPA1, which was derived from the Na\(_{\text{v}}1.7\) intracellular loop 1 and is conserved among the TTXs Na\(_{\text{v}}\) subtypes. Na\(_{\text{v}}\)iPA1 expression in primary sensory neurons (PSNs) of dorsal root ganglia (DRG) produced significant inhibition of TTXs \(I_{\text{Na}}\) but not TTXr \(I_{\text{Na}}\). DRG injection of AAV6-encoded Na\(_{\text{v}}\)iPA1 significantly attenuated evoked and spontaneous pain behaviors in both male and female rats with neuropathic pain induced by tibial nerve injury (TNI). Whole-cell current clamp of the PSNs showed that Na\(_{\text{v}}\)iPA1 expression normalized PSN excitability in TNI rats, suggesting that Na\(_{\text{v}}\)iPA1 attenuated pain by reversal of injury-induced neuronal hypersensitivity. Immunohistochemistry revealed efficient Na\(_{\text{v}}\)iPA1 expression restricted in PSNs and their central and peripheral terminals, indicating PSN-restricted AAV biodistribution. Inhibition of sodium channels by Na\(_{\text{v}}\)iPA1 was replicated in the human iPSC-derived sensory neurons. These results summate that Na\(_{\text{v}}\)iPA1 is a promising analgesic lead that, combined with AAV-mediated PSN-specific block of multiple TTXs Na\(_{\text{v}}\)s, has potential as peripheral nerve-restricted analgesic therapeutics.

Find the latest version:

[https://jci.me/170813/pdf](https://jci.me/170813/pdf)
Peripheral targeted analgesia via AAV-mediated sensory neuron-specific inhibition of multiple pronociceptive sodium channels

Seung Min Shin¹, Brandon Itson-Zoske¹, Fan Fan², Yucheng Xiao³, Chensheng Qiu¹-⁴, Theodore R. Cummins³, Quinn H. Hogan¹, and Hongwei Yu¹*

¹ Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, WI 53226
² Department of Physiology, Medical College of Georgia, Augusta University, Augusta, GA 30912
³ Department of Biology, School of Science, Indiana University-Purdue University, Indianapolis, IN, 46202
⁴ Department of Orthopedic Surgery, Qingdao Municipal Hospital, Qingdao, China 266011

* Corresponding author
Hongwei Yu, Address: Department of Anesthesiology, MEB: M4306, Medical College of Wisconsin, Milwaukee, WI 53226; Email: hyu@mcw.edu; Phone: 414-955-5745, Fax: 414-955-6507

Declaration of Competing Interest. The authors have declared that no conflict of interest exists.
Abstract

This study reports that targeting intrinsically disordered regions of Nav1.7 protein facilitates discovery of sodium channel inhibitory peptide aptamers (NaviPA) for adeno-associated virus (AAV)-mediated, sensory neuron-specific analgesia. A multipronged inhibition of I_{Na1.7}, I_{Na1.6}, I_{Na1.3}, and I_{Na1.1} but not I_{Na1.5} and I_{Na1.8} was found for a prototype, named NaviPA1, which was derived from the Nav1.7 intracellular loop 1 and is conserved among the TTXs Nav subtypes. NaviPA1 expression in primary sensory neurons (PSNs) of dorsal root ganglia (DRG) produced significant inhibition of TTXs I_{Na} but not TTXr I_{Na}. DRG injection of AAV6-encoded NaviPA1 significantly attenuated evoked and spontaneous pain behaviors in both male and female rats with neuropathic pain induced by tibial nerve injury (TNI). Whole-cell current clamp of the PSNs showed that NaviPA1 expression normalized PSN excitability in TNI rats, suggesting that NaviPA1 attenuated pain by reversal of injury-induced neuronal hypersensitivity. Immunohistochemistry revealed efficient NaviPA1 expression restricted in PSNs and their central and peripheral terminals, indicating PSN-restricted AAV biodistribution. Inhibition of sodium channels by NaviPA1 was replicated in the human iPSC-derived sensory neurons. These results summate that NaviPA1 is a promising analgesic lead that, combined with AAV-mediated PSN-specific block of multiple TTXs Navs, has potential as peripheral nerve-restricted analgesic therapeutics.

Keywords: Sodium channels, Neuropathic pain, Dorsal root ganglia, Adeno-associated virus, Molecular therapy
Introduction

Voltage-gated sodium channels (Navs) are key regulators of neuronal excitability and pain sensations (1). Mammals possess nine isoforms of Navs, of which Na\textsubscript{V}1.7, Na\textsubscript{V}1.8, and Na\textsubscript{V}1.9 are preferentially expressed in the primary sensory neurons (PSNs) of dorsal root ganglia (DRG) (2). The prominent roles of these Nav isoforms in human pain have been validated (2). Na\textsubscript{V}1.6, Na\textsubscript{V}1.1, and Na\textsubscript{V}1.3 are also expressed in PSNs and have been reported as possible targets for analgesics (3, 4). Currently, Na\textsubscript{V}1.7 is the leading target among Navs for developing analgesic therapies (5).

Numerous efforts have been made over the last decades to develop selective and effective Na\textsubscript{V}1.7 blockers to treat pain in clinic (6), but the success has been limited. Most of the available small-molecule Na\textsubscript{V}1.7 blockers tested to treat pain are insufficient in target engagement, lack of targeting specificity or selective bioavailability in pain axis, and their global distribution contributes to cardio-toxicity, motor impairments, and CNS side-effects (6). Development of biologics targeting Na\textsubscript{V}1.7 is an alternative growing-trend (7, 8) for analgesia. Na\textsubscript{V}1.7 neutralizing monoclonal antibodies have analgesic efficacy, but the results are inconsistent (6). Tarantula peptide Na\textsubscript{V}1.7 blockers are effective analgesics but have poor membrane permeability, inadequate Na\textsubscript{V}1.7 selectivity, and short half-lives (6). Na\textsubscript{V}1.7-RNAi (6) and CRISPR-dCas9 or ZEN epigenetic Na\textsubscript{V}1.7 suppression for analgesic gene therapy have been proposed (9), but these interventions at mRNA and epigenetic levels have a concern of lacking the specificity of direct channel intervention, reducing safety and permitting off-target effects (6, 10), and anti-Cas9 immunity creates additional challenge for CRISPR gene therapies (11).
Small peptides derived from pronociceptive ion channels as functionally interfering peptide aptamers (iPA) are highly effective and selective, allowing block of specific nociceptive signaling (12, 13). Intrinsically disordered regions (IDRs) of ion channel proteins are commonly engaged in promiscuous interactomes, which are important players in multiple signaling regulations and are recognized as new and promising drug targets (14). We speculated that Na\textsubscript{V}1.7-IDRs contain short functional IDR domains that could play critical roles in modulating Na\textsubscript{V}1.7 functions and can be developed as Na\textsubscript{V}1.7iPAs (1.7iPA). Furthermore, the high-level conservation of Na\textsubscript{V} subtype sequences implies that a given 1.7iPA could interact with other Na\textsubscript{V} subtypes that have homologous sequences to Na\textsubscript{V}1.7 and thereby enable multipronged engagement of Na\textsubscript{V} subtypes. Because multiple PSN-Na\textsubscript{V}s contribute to nociceptive electrogenesis and pain pathogenesis, it is conceivable that AAV-mediated expression of such multipronged NavIPA restricted in DRG-PSNs to inhibit several pronociceptive Na\textsubscript{V}s could be an analgesic advantage compared to block of only a single Na\textsubscript{V} subtype (15-17).

We here describe a strategy by which highly selective and nontoxic Na\textsubscript{V}iPAs were designed and developed from Na\textsubscript{V}s-IDRs. A prototypic NavIPA1 derived from Na\textsubscript{V}1.7 intracellular loop 1 and conserved in TTXs Na\textsubscript{V} subtypes showed multipronged inhibition of Na\textsubscript{V}1.7, Na\textsubscript{V}1.6, Na\textsubscript{V}1.3, and Na\textsubscript{V}1.1 channels. NavIPA1 expression in rat PSNs rendered significant TTXs but not TTXr I\textsubscript{Na} inhibition. AAV-mediated NavIPA1 expression selectively in the PSNs responsible for pain pathology in rat pain model produced efficient analgesia while avoiding off-site biodistribution that causes side effects. Together, these results indicate that AAV-mediated PSN-specific, combined block of multiple nociceptive Na\textsubscript{V}s, has potential for future therapeutic development.
In silico design of 1.7iPAs from Na\textsubscript{v}1.7-IDRs

The candidate iPAs were designed through a priori strategy aimed to define the short linear functional disordered peptides from the intrinsically disordered domains (IDDs) (12), initially from Na\textsubscript{v}1.7 protein IDRs, on the hypothesis that Na\textsubscript{v}1.7 IDDs contain the functional sequences that modulate Na\textsubscript{v}1.7 channel function. We analyzed the full length of the rat Na\textsubscript{v}1.7 protein sequence using DisorderEd PredictIon CenTER (DEPICTER), which combines 10 popular algorithms for IDR predictions within the primary sequence, based on amino acid (aa) biophysical features for the protein’s disordered ensemble (18). Results return a score between 0 and 1 for each residue, indicating the degree to which a given residue is part of an ordered or disordered region (residues with scores >0.5 are considered as disordered). Results revealed clear order-to-disorder transitions where Na\textsubscript{v}1.7 transmembrane (TM) domains and intracellular portions join, and scores indicate a disordered nature of Na\textsubscript{v}1.7 intracellular and terminal regions (Figure 1A-1C). Specifically, the most extensive IDRs are in the intracellular loops (ICL), while protein TM domains are highly ordered.

Potential phosphorylation sites in the Na\textsubscript{v}1.7 sequence were identified using Disorder Enhanced Phosphorylation Predictor (DEPP) (19). Results showed that most potential phosphorylation residues (serine, threonine, and tyrosine with high DEPP scores) reside in Na\textsubscript{v}1.7-IDRs, particularly in the IDRs within the ICL1 and ICL2 (Figure 1D). Na\textsubscript{v}1.7-IDRs feature as potential protein-protein interaction (PPI) binding sites, suggesting these IDRs could contain key binding motifs or domains of the Na\textsubscript{v}1.7 regulatory signaling interactome (20). These observations predict
that focusing on the Nav1.7-IDRs could be an avenue for identifying short peptides effective in modulating Nav1.7 channel function.

The potentially functional domains within the Nav1.7-IDRs (21) were further analyzed using SLiMPrints (22), which predict short linear motifs (SLiMs) based on strongly conserved primary aa sequences, followed by filtering based on the prediction scores (22). The enumerated motifs predicted within Nav1.7-IDRs suggest many possible functional peptides as ‘hot-spots’ of functional IDDs, including proteolytic cleavage sites, ligand binding sites, post-translational modification (PTM) sites, and sub-cellular targeting sites. Nine peptides were designed computationally based on IDR scores and phosphorylation sites and were the focus as 1.7iPA candidates for further testing (Figure 1E, 1B).

**Constructs of 1.7iPAs and transfection expression**

AAV expression plasmids containing transgene expression cassettes encoding various GFP-1.7iPA chimeras were constructed. Specifically, the sequences for interchangeable iPA peptides were cloned with a linker sequence (GLRSRAQASNSAVDGTAGPGS) as we described previously (23), to form a chimeric transgene in a GFP-linker-iPA orientation transcribed by a hybrid human cytomegalovirus (CMV) enhancer/chicken β-actin (CBA) promoter. This generated pAAV-CBA-GFP-1.7iPAs (pAAV-1.7iPA) expression plasmids, in which the oligonucleotide encoding the interchangeable 1.7iPAs are inserted at the 3′ end of GFP (Figure 1F). The predicted protein structure analysis of GFP1.7iPA1 by I-TASSER tool (24) shows an unfolded and extended, highly flexible structural ensemble of linker-1.7iPA1 (Figure 1G), which is compatible with a
well-exposed mode binding to targets. Similar structures were also identified by I-TASSER for other GFP1.7iPAs (Supplemental Figure 1).

**Inhibition of Nav1.7 current (I_{Na1.7}) in HEK1.7 cells by 1.7iPAs**

The stable expression of each construct was verified by transfection into HEK293 cells stably expressing human wild-type Nav1.7 (HEK1.7 cells), followed by immunoblots (IB). Representative tests for GFP linker (GFP), 1.7iPAs (1, 2, 3, 4, 6) were shown (Figure 1H, I). Initial screening experiments by whole-cell voltage-clamp of I_{Na1.7} in HEK1.7 cells, transfected with plasmids encoding nine 1.7iPAs (1.7iPA1-9), were performed to characterize the I_{Na1.7}. The presence of 9 different 1.7iPAs in HEK1.7 cells on peak I_{Na1.7} density (3 days after transfection) was summarized in Figure 1F, in which the data points recorded by at least 2 replicates were combined. The results showed that 1.7iPA1, 4, and 6 produced ~68%, ~59%, and ~54% reduction of peak I_{Na1.7} density, respectively, while 1.7iPA2 increased peak I_{Na1.7} density (~35%). Transfection with plasmids expressing the GFP linker and 1.7iPA3, 5, 7, 8, and 9 showed no significant effects on peak I_{Na1.7} density, compared to sham transfected (transfection with PEI but no plasmid) HEK1.7 cells. These experiments thus identified 1.7iPA1 and 1.7iPA4 (both derived from ICL1), as well as 1.7iPA6 (from ICL2), as effective iPAs (>50% I_{Na1.7} inhibition). We next focused on the validation of I_{Na1.7} inhibition and channel kinetics by 1.7iPA1, 4, and 6 on HEK1.7 cells in new experiments. These results replicated the prior screening testing results of peak I_{Na1.7} densities and showed that the steady-state activation and fast inactivation kinetics of Nav1.7 channels were not significantly affected in the presence of 1.7iPA1, 4, and 6 (Figure 2). The 1.7iPA1 peptide is polyampholytic, enriched with 38.6 % positively charged arginine or lysine (17/44), 22.7% of serine (10/44), 18.1% acidic residues (8/44), and is highly conserved between
rodents and humans (Figure 2F). Searching databases revealed that two serine phosphorylation and two lysine acetylation sites were assigned in high throughput (proteomic discovery mass spectrometry) studies (25) and a nuclear localization signal was predicted by SeqNLS (26). These analyses strongly suggest that 1.7iPA1 is a functional IDD peptide. Since 1.7iPA1 revealed higher inhibition of I_{Na1.7} and was highly homologous to other TTXs Nav subtypes (see further), we selected it as a prototype and named NaviPA1 for further ‘hit to lead’ characterization.

Specificity of NaviPA1 occupancy to various voltage-gated ion channels

Development of Nav1.8 stable expression system based on HEK cells. To assess the potential of NaviPA1 in affecting I_{Na} conducted by Nav1.8 channels, we developed stable expression of recombinant human Nav1.8 heterologous systems based on HEK cells (HEK1.8). Stable Nav1.8 expression was confirmed by immunoblots of Nav1.8α and Naβ2 in the cells after at least 10~20 rounds of G418 selection (400-800 µg/mL), followed by single-cell isolation using BIOCHIPS Single-cell Isolation Chip (ThermFisher, Rockford, IL). Both Nav1.8α and Naβ2 were found to be highly expressed in the cell membrane. Functional Nav1.8 expression was identified by the presence of slowly inactivating inward I_{Na} elicited by voltage steps from -140 mV to +80 mV during the whole-cell voltage-clamp recordings and the averaged peak I_{Na1.8} density in ~85% of the HEK1.8 was >0.5 nA, and I_{Na1.8} was sensitive to a Nav1.8 channel blocker, A803467 (Alomone, Jerusalem, Israel) and resistant to high concentration of TTX (5µM, Tocris Bioscience, Pittsburgh, PA). We used this HEK1.8 cell line for the initial screening tests of the NaviPA1 on I_{Na1.8}. In comparison, I_{Na1.8} amplitudes in CHO-Nav1.8 cells were generally less than 100 pA, which was insufficient for our experimental needs (Supplemental Figure 2).
Selectivity of NavPA1 on ion channel occupancy. Nav subtype stable cell lines based on HEK cells used for this experiment included HEK1.1, 1.3, 1.6, 1.5, and 1.8. Sequence alignments identified high-level homology of NavPA1 with the corresponding sequences of TTXs Nav1.1, 1.3, and 1.6, but much less homologous to TTXr Nav1.5, 1.8, and 1.9 (Figure 3A, B). Expression of NavPA1 (fused to GFP) resulted in a significant block of $I_{Na}$ conducted by fast-activating and inactivating Nav1.1, Nav1.3, and 1.6 (Figure 3C-E). No effects on $I_{Na1.5}$ and $I_{Na1.8}$ were observed in the presence of NavPA1 in the HEK1.5 and HEK1.8 cells (Figure 3F-G) or in ND7/23 cells transiently transfected with Nav1.8 (Supplemental Figure 3). We did not test NavPA1 against Nav1.9 channels as the expression cell line is unavailable; however, $I_{Na1.9}$ inhibition by 1.7iPA1 is not expected since there is no sequence homology of NavPA1 to Nav1.9. The negative effects of NavPA1 on potassium current (BK $I_{Kv}$) were found in NG108-15 cells which naturally express potassium channels (12), and no effects on high-voltage activated (HVA) $I_{Ca}$ were recorded on AAV-mediated NavPA1 expression in DRG-PSNs. Potent $I_{Na1.7}$ inhibition by NavPA1 was also confirmed in neuronal NG108-15 cells and F11 DRG-neuronal-like cells that naturally express Nav1.7. These experiments showed no pleiotropic effects of NavPA1 on either BK potassium channels or HVA $I_{Ca}$ (Supplemental Figure 4).

AAV6-mediated NavPA1 expression in DRG-PSNs inhibits TTXs $I_{Na}$ but not TTXr $I_{Na}$. Because no heterologous system or cell lines can fully mimic the in vivo conditions of sensory neurons, we further tested the functional inhibition of $I_{Na}$ by NavPA1 in DRG-PSNs. AAV6 vectors encoding GFP-fused NavPA1 were generated and injected into lumbar (L) 4/5 DRG of naïve rats (male), and acutely dissociated sensory neurons from DRG were tested at 4 weeks post-injection. AAV6 encoding GFPlinker and NP (1.7iPA3) which was derived from the N-terminus
of Nav1.7 (Figure 1) and showed no impact on $I_{\text{Na}}$ after being transfected into HEK1.7 (Figure 1, 2) were used as the control. A voltage protocol was adopted that demonstrates successful separation of TTXr $I_{\text{Na}}$ (Nav1.8-like) and TTXs $I_{\text{Na}}$ in dissociated DRG neurons (27, 28), comparable to the recordings after addition of TTX (1.0 µM) in bath solution (Supplemental Figure 5A, B). Whole-cell voltage-clamp recordings by the voltage protocol from small/medium-sized PSNs (≤35 µm) showed that AAV-mediated expression of NavI1Pi produced significant inhibition of total and TTXs $I_{\text{Na}}$ whereas it produced no significant inhibition on TTXr $I_{\text{Na}}$ (Figure 4A-C).

**Inhibition of TTXs $I_{\text{Na}}$ by NavI1Pi in human iPSC-derived sensory neurons.** To study the relevance of our findings in a human context, we used human induced pluripotent stem cells (iPSC)-derived sensory neurons (hiPSC-SNs, female, Anatomic, Minneapolis, MN) (29) to test whether inhibition of TTXs $I_{\text{Na}}$ by NavI1Pi1 represents a meaningful and quantitative index of the functional lead in human sensory neurons. This also allowed examination NavI1Pi1 without potential overexpression effects in HEK-NaV cells. The hiPSC-SNs were differentiated to small-sized PSN morphology with a soma diameter around 20~25 µm and developed extensive neurites after 4-7 days in vitro (DIV) differentiation cultures, indicating that these cells were efficiently committed to the neuronal lineage. We used lentivector (LV-GFP) (Supplemental Figure 6) to test hiPSC-SN transduction efficiency. We have succeeded in expressing NavI1Pi1 and 1.7NP (control) in the differentiated hiPSC-SNs by LV transduction at multiple of infection (MOI)=5 (Figure 4D, E). Electrophysiological recordings were performed on the hiPSC-SNs (DIV25) with TTX (1 µM) in the bath solution and TTXr/TTXs $I_{\text{Na}}$ were separated by a subtraction protocol (27). To prevent the TTX effect, a voltage manipulation similar to DRG neuron recording was used.
Additionally, a protocol to isolate somatic $I_{\text{Na}}$ by a brief prepulse to voltage near spike inactivating hiPSC-SN axonal spike but not somatic spikes was adopted (30). Results showed that Na\textsubscript{ViPA1} significantly inhibited TTXs $I_{\text{Na}}$ but not TTXr $I_{\text{Na}}$ in differentiated hiPSC-SNs (DIV25) (Figure 4F-G), comparable to rat DRG-PSNs. No effects were observed for BK $I_{\text{Kv}}$ and HAV $I_{\text{Ca}}$ recorded (DIV21) from hiPSC-SNs in the presence of Na\textsubscript{ViPA1} (Supplemental Figure 7). Results indicate that inhibitory efficacy of Na\textsubscript{ViPA1} on TTXs $I_{\text{Na}}$ defined in cell lines and rat DRG-PSNs are translatable to human PSNs.

**Molecular mechanisms of Na\textsubscript{ViPA1}: initial testing**

We first validated the specificity of Na\textsubscript{V}1.7 antibody by immunoblotting (IB) using the cell lysates prepared from naïve HEK cells, stable cell lines expressing different Na\textsubscript{V} isoforms, and 50B11 rat DRG neuronal cells. This Na\textsubscript{V}1.7 antibody (Alomone ASC-008) was raised by an antigenic peptide corresponding to amino acid residues 446-460 of rat Na\textsubscript{V}1.7 and no significant sequence homologous with other Na\textsubscript{V} isoforms. Results showed that the Nav1.7 antibody detected full-length Na\textsubscript{V}1.7 only in HEK1.7 cells, but not other Na\textsubscript{V} isoforms and 50B11 cells that naturally do not express physical and functional Na\textsubscript{V}1.7 (31) (Figure 5A). By immunohistochemistry (IHC) on rat tissue sections, Na\textsubscript{V}1.7 expression was detected with high immunoreactive density in small/medium-sized PSNs using the Na\textsubscript{V}1.7 antibody, and Na\textsubscript{V}1.7 was also detected in spinal cord dorsal horn (SDH), sciatic nerve, and cutaneous terminals in hindpaw (Figure 5B-E), with the patterns similar to the prior report (32). These results confirmed the specificity of the Na\textsubscript{V}1.7 antibody to detect Na\textsubscript{V}1.7 expression by IHC and immunoblot.
Since Nav1.7 is an integral membrane protein, we therefore tested whether Nav\textsubscript{iPA1} expression in the HEK1.7 cells would interrupt Nav1.7 intracellular trafficking. Our results do not support this mechanism since no clear reduction of membrane Nav1.7 protein was evident in the fractionized preparations, from HEK1.7 cells transfected with Nav\textsubscript{iPA1} and controls (Figure 5F). Studies have shown that IDRs in the membrane proteins engage in interactions with the membrane (33). To test whether Nav\textsubscript{iPA1} interference of Nav1.7 might be via direct block of Nav1.7, GFP affinity pull-down by ChromoTek GFP-Trap (ChromoTek, Rosemont, IL) was performed after transfection of GFP-Nav\textsubscript{iPA1} in HEK1.7 cells using GFPlinker (GFP) and GFP-1.7iPA2 (Figure 1) as the controls. Cell lysates were prepared by a lysis buffer containing 0.5% Nonidet p40, a ‘non-denaturing’ mild lysis detergent, for preventing interaction breaking and maximizing the retention of Nav\textsubscript{iPA1}-protein interactions (34). Immunoblots verified full-length Nav1.7 protein trapped in the GFPNav\textsubscript{iPA1} pull-down sample but not in controls (Figure 5G, repeat twice), and nLC-MS/MS detection of unique hNav1.7 peptides (Table 1) confirmed hNav1.7 on the excised band from silver-stained sodium dodecyl sulfate-polyacrylamide electrophoresis (SDS-PAGE) gel (Figure 5G, right panel) of GFPNav\textsubscript{iPA1} affinity pull-down sample. These results indicate that Nav\textsubscript{iPA1} block of Nav1.7 channel activation could be via binding to the Nav1.7 protein, i.e., an intra-molecular domain-domain interaction (intraDDI) (35). It has been reported that polybasic IDRs in transmembrane proteins preferably bind to negatively charged lipids (36, 37). We reasoned that Nav\textsubscript{iPA1} might be able to bind phosphoinositides, and this hypothesis was tested by using phosphatidylinositol phosphate (PIP) strips (Echelon PIP Strip, Salt Lake City, UT). GFPNav\textsubscript{iPA1} and GFP (control) were transfected into neuronal NG108-15 cells, and cell lysates were prepared by a RIPA buffer containing 0.1% SDS and 1% Triton X100 (strong detergents) and 1% deoxycholate (anionic detergent) for maximally denaturing to break Nav\textsubscript{iPA1} PPI complex
formations. Silver stain after SDS-PAGE gel showed clean purification of GFP and GFPNav1.7 (Figure 5H) and samples were applied to the PIP strips. Results (Figure 5I, repeat twice) showed that GFP Nav1.7 was efficiently bound to a number of anionic PIPs, PIP2, phosphatidic acid (PA), and phosphatidylserine (PS). In contrast, affinity pull-down GFP did not show clear binding to lipid spots as previously reported (38). This is consistent with the reports that basic residues, often clustered in IDRs, can modulate membrane protein functions by binding via electrostatic interactions with lipids (39, 40).

Nav1.7 is a polybasic arginine/lysine and serine-enriched peptide (Figure 2F). Protein-conserved polybasic domains with adjacent serine PTMs often play roles in protein function (41-43). We designed experiments to examine the role of polybasic NLS and multiple adjacent polyserine in the function of Nav1.7. Initial tests were performed by generating Nav1.7mt1 (GFP-fused) in which alanine substitution for ten serine residues within Nav1.7 was made and Nav1.7mt2 (GFP-fused) was generated by alanine substitution for nine arginine or lysine within the predicted polybasic NLS of Nav1.7 (Figure 6A). ICC showed that nuclear localization of Nav1.7 (HEK1.7 cell transfection) was observed in Nav1.7 and Nav1.7mt1 but diminished in Nav1.7mt2 (Figure 6B-E). With a comparable transfection rate at ~40% for each construct, immunoblots revealed that Nav1.7 was detected in the extracted cytosol, membrane, and nuclear samples and that the membrane-binding and nuclear entry signals in Nav1.7mt1 were comparable to Nav1.7 but both vanished in Nav1.7mt2. Full-length Nav1.7 was enriched in the membrane samples as shown in Figure 5F and the presence of Nav1.7, mt1, and mt2 in HEK1.7 cells appeared not to impede Nav1.7 protein membrane integration (Figure 6F). Whole-cell voltage-clamp recording showed that I_{Na1.7} in the presence of Nav1.7mt1 and mt2 was
comparable to naïve and GFPNP transfected HEK1.7 cells, suggesting that both polybasic arginine/lysine and multiple adjacent serine residues were required for NaviPA1 inhibitory effect on Na1.7 current. To further map the critical serine sites, we generated additional NaviPA1mt3-mt6 with alanine substitution for dual or triple serine residues (Figure 6A). Whole-cell voltage-clamp recording showed that NaviPA1mt3 and 5 with alanine substitution at different serine sites lost inhibitory effects on I_Na1.7 after transfection to HEK1.7 cells while mt4 and mt6 showed a significant block of I_Na1.7 (Figure 6G, H). As expected, NaviPA1mt1 and mt2 did not change I_Na1.8 after being transfected to HEK1.8 cells, similar to NaviPA1 (Supplemental Figure 8). These data suggest that conserved polybasic NLS and multiple adjacent serine residues within the NaviPA1 are synergistic for I_Na1.7 inhibition. The polybasic motif determines for polar association with the plasma membrane and nuclear entry of disordered NaviPA1 peptide and multiple adjacent serine residues are required for NaviPA1 inhibitory effect to I_Na1.7. However, the full-length Na1.7 membrane integration, which is determined by its TM domains but not intracellular sequences, was unaffected in the presence of NaviPA1 (Figure 6F).

Future delineation of the properties of serine and other residue PTMs within NaviPA1 underlying inhibition of various TTXs I_Na in sensory neurons and investigation of whether the presence of NaviPA1 might undermine TTXs Nav channel activity via decoying interaction, diminishing PTMs in the full-length protein, and/or altering intradomain effects are of interest from both pathophysiological and therapeutic perspectives. Our goal in this study is to develop a strategy of peripherally targeted analgesia via AAV-mediated sensory neuron-specific inhibition of sodium channels. Therefore, in the following in vivo experiments, we focused on testing whether DRG-PSN-targeted expression of NaviPA1 is effective in attenuating neuropathic pain behaviors.
Analgesia after intraganglionic delivery of AAV-Nav\textit{i}PA1 in rats after TNI

We first conducted a pilot in vivo analgesia testing. High-titer and high-purity of AAV6-GFPNav\textit{i}PA1 (AAV6-Nav\textit{i}PA1) and control AAV6-GFPNP (AAV6-NP) were generated and injected into the L4/5 DRG of adult male rats. Three weeks after DRG-AAV injection, TNI was induced, and subsequent sensory behavior evaluation was performed weekly for an additional 5 weeks, after which tissues were harvested for IHC characterization of transgene expression. Results (Supplemental Figure 9) showed that AAV6-Nav\textit{i}PA1 injection reduced TNI-induced mechanical and cold sensitization. IHC revealed efficient Nav\textit{i}PA1 (fused to GFP) expression in DRG neurons and their peripheral (cutaneous) and central terminals (SDH). These data indicate that sustained expression of the Nav\textit{i}PA1 selectively in the PSNs of the pathological DRG after TNI prevented development of pain behaviors.

Treatment of established neuropathic pain by DRG-AAV6-Nav\textit{i}PA1 in male rats

We next extended experiments to evaluate the effectiveness of DRG-AAV6-Nav\textit{i}PA1 in a more clinically relevant design for reversal of established pain behaviors, including both evoked responses as well as spontaneous ongoing pain following TNI. In the experimental design, the sensitivity to mechanical and thermal cutaneous stimulation was assessed at baseline and weekly after TNI for 2 weeks before AAV injection. Thereafter, rats were randomized to receive DRG injection of either AAV6-Nav\textit{i}PA1 or control AAV6-NP into the L4/L5 DRG ipsilateral to TNI, after which sensory behaviors were evaluated weekly for additional 6 weeks. As a terminal experiment, Gabapentin (GBP,100mg/kg, i.p.)-induced conditioned place preference (CPP) test was performed in both groups to evaluate spontaneous pain (12, 44). Behavior measures before
AAV injection on the 14th day after TNI were used as a treatment baseline (tBL) to evaluate effectiveness of vector treatments (Figure 7A, B). Tissues were harvested for IHC characterization of transgene and target gene expression and for whole-cell current-clamp of neuronal excitability on dissociated DRG neurons.

All rats developed multiple modalities of pain behaviors 2 weeks after TNI, including lowered threshold for withdrawal from mild mechanical stimuli (vF), more frequent hyperalgesic-type responses after noxious mechanical stimulation (Pin), and hypersensitivity to heat and acetone stimulation. These behaviors persisted after injection of the control AAV6-NP during the 6 weeks of observation course. In contrast, rats injected with AAV6-NaviPA1 showed a gradual reversal of these changes, which were maintained throughout and predicted to outlast the observation period (Figure 7C-F). For our protocol of treating existing pain, we converted the measures on the 14th day after TNI and before AAV treatment (tBL) as the peak pain intensity (100%), and the measures of each sensory modality after treatment were normalized to the measures at the tBL and the percentage of pain relief for each modality at multiple time points was calculated (Figure 7C1-F1). Summed average pain relief in the 6-week treatment course showed 52%, 49%, 69%, and 67% reduction of vF-, Pin-, Cold-, and Heat-stimulated mechanical and thermal pain behaviors, respectively (Figure 7G). Using a biased CPP paradigm (45), the effect of AAV-NaviPA1 treatment on the affective aspect of spontaneous pain was evaluated. None of the animals in either group were excluded from study because of their baseline preference/avoidance for a chamber (45). A significant GBP-induced CPP effect was observed in the TNI rats injected with AAV6-NP indicating ongoing pain, while there was no significant difference in the time spent in the initially nonpreferred chamber during baseline vs. testing period in AAV-NaviPA1 treated TNI animals,
indicating that AAV-NaviPA1 treatment significantly relieved on-going spontaneous pain (Figure 7H).

Histological examination (Figure 8) determined the in vivo transduction rate for AAV6-NaviPA1 in the 6th week after vector injection. The NaviPA1-positive neurons (GFP) comprised 37 ± 4 % (1283 out of 3447 total neuronal profiles) identified by a pan-neuronal marker β3-tubulin (n = 4 DRG, 3-4 sections per DRG, selected as every fifth section from the consecutive serial sections). Transduced DRG neurons included the full-size range of the PSNs that also expressed Nav1.7 and Nav1.6, and expression showed multiple subcellular localizations, preferably in PSN cytosol. Positive GFP signals were not detected in GFAP-positive perineuronal glial cells. GFP signals were also detected in the ipsilateral dorsal horn, sciatic nerve, and cutaneous afferent terminals.

These findings together demonstrate that DRG injection of AAV6-encoded NaviPA1 induced NaviPA1 expression restricted to the PSNs of injected DRG and their peripheral and central processes. This strategy via AAV6-mediated expression of NaviPA1 selective in the sensory neurons of the anatomically segmental DRG responsible for pain pathophysiology has clear analgesic effectiveness in normalizing the established peripheral hypersensitivity for both evoked and spontaneous pain behavior in the rat model of peripheral injury-induced neuropathy.

Reversal of PSN hyperexcitability by AAV6-NaviPA1 treatment (male rats)

Increased excitability of nociceptive PSNs is a fundamental process underlying neuropathic pain (46). We therefore examined whether AAV6-NaviPA1 treatment reverses the enhanced neuronal excitability of nociceptive PSNs following TNI (12, 47), using the whole-cell current-clamp AP
recording of DRG dissociated neurons from rats after the treatment protocol shown in Figure 7B.

Although TNI results in DRG containing co-mingled injured and uninjured axons, nerve-injury can induce an increase of voltage-gated ion channel activity in both axotomized neurons and adjacent intact neurons, leading to similar electrophysiological (EP) changes and increased discharge frequency in axotomized and neighboring intact DRG neurons (48, 49), possibly through interneuronal signaling and coupling (50). We therefore recorded from randomly chosen small/medium-sized neurons (<35 μm in diameter) (51) in the cultures from dissociated L4 and L5 DRG. Transduced neurons were identified by GFP fluorescence, and excitability was evaluated by measuring rheobase and repetitive action potential (AP) firing during 250ms current pulses stepping from 100pA and 280pA current injection. Results showed that the averaged rheobase in the neurons from TNI rats was significantly decreased and, in response to a step stimulus, the frequency of APs evoked in neurons from TNI rats was significantly increased, compared to sham controls. These were normalized in the transduced neurons after AAV6-NaviPA1 treatment, whereas NP-transduced neurons had no significant effects (Figure 9). These findings indicate that reversal of nerve injury-induced sensory neuronal hyperexcitability by NaviPA1 may contribute to its analgesic effects in attenuation of neuropathic pain behaviors, i.e., conduction block of TTXs NaV ion channels selectively in PSNs leads to a decrease in neural excitability, resulting in mitigation of pain behaviors.

**Analgesia of DRG-AAV6-NaviPA1 treatment in female TNI rats**

Sex differences exist in experimental and clinical pain and in responsivity to interventions (52). We therefore next tested whether DRG-AAV6-NaviPA1 treatment is also effective in attenuating hypersensitivity induced by TNI in female animals, using the protocol similar to the tests in male
animals (Figure 7). The same batch preparation of AAV6-NavPA1 and AAV6-NP tested in male rats was used for injection. Results showed that the female rats displayed similar phenotypic development of hypersensitivity after induction of TNI to male rats and that both evoked mechanical/thermal hypersensitivity and GBP-CPP responses were normalized after AAV6-NavPA1 treatment, demonstrating comparable analgesic effects (Figure 10A-E) to the male animals. IHC on the DRG sections from female TNI rats 6 weeks after AAV6-NavPA1 injection also revealed GFP-NavPA1 expression profile comparable to male rats (Figure 9F-G), and the in vivo transduction rate was 39±8 % (766 out of 1983 total Tubb3-positive neuronal profiles). Thus, although not rigorously compared, treatment effects were comparably concordant between the sexes, suggesting that a sexual dimorphism seems not apparent for both pain behavior phenotypes after TNI and in responsivity to DRG-AAV6-NavPA1 treatment in our studies (12).
Discussion

Sustained peripherally targeted analgesia without risk of addiction is a global unmet medical need (53-55). Nav1.7 is currently a leading target for analgesic pharmaceutics. However, ample evidence demonstrates that multiple sensory neuronal NaVs contribute to nociceptive electrogensis and pain pathogenesis (15, 56). Here, we reported that targeting Nav-IDRs facilitated the discovery of NaviPAs. A prototypic NaviPA1, initially derived from Nav1.7, is highly conserved in sequences among TTXs Navs, and accordingly, demonstrated multipronged inhibitory feature to TTXs INa conducted by Nav1.7, Nav1.6, Nav1.3, and Nav1.1 but no effect on TTXr INa conducted by Nav1.8 and Nav1.5. NaviPA1 expression in DRG-PSNs produced selective inhibition of TTXs INa but not TTXr INa. DRG delivery of AAV6-encoded NaviPA1 significantly attenuated established nerve injury-induced pain behaviors in male and female animals for both evoked mechanical and thermal hypersensitivity and ongoing or spontaneous pain behaviors, the symptoms commonly found in patients suffering from multiple types of painful neuropathy (57). Additionally, blockade effects of TTXs INa by NaviPA1 were replicated in the hiPSC-SNs, supporting a translational potential. Because several different types of NaVs in sensory neurons combine to trigger nociceptor electrogensis required for AP trains (1), block of several of these specific in DRG-PSNs is conceived to be a therapeutical advantage for neuropathic pain.

Chronic pain in almost all cases is maintained by ongoing afferent hyperactivity originating from peripheral pathological sources (53, 58, 59). Thus, development of novel peripheral-acting strategies for pronociceptive Nav inhibition in the PSNs would be an ideal approach for clinical pain treatment (2, 54). Our strategy described here includes a approach by which highly selective
and nontoxic NaviPA1 is designed and developed from Nav-IDRs, which is delivered by using AAV to the pathological DRG. PSN-restricted inhibition of multiple pronociceptive TTXs NaVs is predicted to have advantages for DRG-targeted analgesia, as a recent expert commentary states that “disappointing analgesic pharmaceutics after a single Nav1.7 inhibition might correlate to the facts that the excitability of neurons is determined by several different Nav channels and targeting just one may not be sufficient by itself” (60). It is known that human subjects and animal models that are heterozygous for null mutations of Nav1.7 are normal in sensory phenotypes. Thus, AAV-mediated NaviPA1 expression restricted in DRG-PSNs may induce analgesia via a combined partial inhibition of Nav1.7, Nav1.6, Nav1.3, and Nav1.1, while avoiding undesirable side-effects otherwise due to global distribution of small molecule inhibitors. Although PSN somata in DRG are anatomically isolated from each other and are not synaptically interconnected, most DRG-PSNs are transiently depolarized when axons of neighboring neurons of the same ganglion are stimulated repetitively (61). This coupled activation occurs among various-sized neurons including small-diameter nociceptors and large-diameter low-threshold mechanoreceptors (50). Therefore, although AAV produces incomplete sensory neuron transduction, transduced neurons can induce a reduction of pronociceptive ion channel activity in both transduced neurons and adjacent non-transduced neurons, leading to similar electrophysiological changes. Another possible advantage is that, unlike gene therapy strategies such as RNAi (62) and CRISPR-dCas9 or ZEN epigenetic suppression (9) that irreversibly reduce the production of a target protein, which is potentially problematic (63); AAV-mediated NaviPA1 expression selective in PSNs provides sustained and restricted blockade of electrogenesis on multiple TTXs-NaVs without abrogating proteins per se, providing specific functional interference. A complete block of Nav1.7 activity is
not intended since it may induce a state of total insensitivity to pain where unintended self-injury would occur (64).

Pain-sensing PSNs can become hyperexcitable in response to peripheral nerve injury, which in turn leads to the development of neuropathic pain. Multiple lines of evidence from both preclinical and clinical studies demonstrate that block of peripheral nociceptive input can effectively relieve pain symptoms including spontaneous pain (65, 66). Therefore, treatments targeting the peripheral PSNs both avoid CNS side effects and also are likely to succeed. Indeed, a recent expert commentary states that “activity in primary afferent neurons represents a ‘low-hanging target’ in the development of safe therapies” for patients with chronic pain (53). Delivering drugs to the DRG is well-developed and safe, for instance, as used by anesthesiologists for regional blockade and by pain physicians for diagnosis and treatment of radiculopathy (67). Injection into the DRG has minimal consequences in preclinical models (68). It has also been demonstrated that unintentional intraganglionic injection commonly accompanies clinical transforaminal epidural steroid injection (67), a very common procedure with minimal risk of nerve damage. Thus, the PSNs are particularly suitable for targeting new analgesic treatments, especially at the levels of associated pathological DRG (54, 69). A recent study reports that central nervous system gene therapy by intravenous high-dose AAV causes asymptomatic and self-limited DRG inflammation and mild PSN degeneration in primates (70). Since these changes are very minor in comparison to the those induced by painful and neuropathic conditions that AAV injection would treat, this is unlikely to become a barrier to the clinical application of our approach.
In preclinical models, direct DRG delivery of AAVs encoding analgesic biologics can provide relief in chronic pain, with high transduction efficiency, flexibility for selective segmental localization, and minimal behavior changes attributable to the surgical procedure (71). In parallel, injection techniques are being advanced to achieve minimal invasive delivery of biologics for future clinical pain therapy (72, 73). Small peptides derived from the target protein sequences can serve as decoy molecules to selectively interfere with the function of their target signaling proteins by preemptively binding to them (13). We have successfully employed this strategy in rat models to induce analgesia by block of T-type/Cav3.2 channel functions (12) and by blocking membrane trafficking of Cav2.2 channels via interrupting its interactions with the structural protein of collapsin response mediator protein 2 (CRMP2) (13). Here, we extend the applicability of DRG-AAV strategy to the analgesic effectiveness of multiple PSN TTXs NaVs blockade for neuropathic pain. These encouraging results that indicate efficacy and tolerability, if further validated for long-term efficacy and minimal side-effects, suggest the transformational potential of the approach for developing addiction-free peripheral pain therapeutic agents. Beyond peripheral nerve injury-induced pain, dysfunctional NaVs have been found in various pain conditions, such as osteoarthritis (OA) that is frequently highlighted as an unmet medical need. Thus, for pain conditions like OA, targeting the TTXs NaVs might be therapeutically useful (74, 75).

While our studies illustrate the power of rational analgesic peptide drug design strategy and provide encouraging results, we acknowledge several limitations in the current study. Different sodium channels traffic to distinct subcellular locations of PSNs (membrane, terminals, nodes of Ranvier, etc.), and the regulation of this process may provide several options to control neuronal excitability in different pathophysiological contexts. Injury-induced peripheral hypersensitization
associated with Nav malfunction affects multiple sites of the peripheral sensory nervous system, including augmented pain perception in the peripheral terminals, enhanced nociceptive signal transduction in PSN soma and T-junction, and increased neurotransmission in the spinal dorsal horn. At this early stage, our studies did not investigate differential actions by block of TTXs Navs along the pathway of peripheral nociceptors, nor did the results rule out the possibility that block of TTXs Navs reduces pain by inhibiting afferent hyperexcitable input (76), thus indirectly modulating spinal cord and brain antinociceptive control circuits. Another limitation is that the molecular mechanism of NaviPA1 functioning remains incompletely delineated. Our study has verified lack of pleiotropic effects on BK and calcium channels, but we cannot rule out the possibility of peptide interacting with other unknown targets that mediate protein binding. Theoretically, if the peptide binds to membrane via a lipid mechanism, it might mediate the PM-targeting of a wide array of proteins carrying specialized domains enriched with positive charges. Delineation of the mechanisms in sensory neurons in future investigation is critical for the assessment of therapeutic efficacy and potential side effects.

Although we have shown that polybasic NLS and multiple adjacent serine residues are required for NavPA1 function, phosphorylation-dependent binding of NavPA1 to the membrane appears unlikely to be essential because serine phosphorylation will neutralize the positive charge of NavPA1. It has been reported that polybasic peptide with nonphosphorylatable serine shows strong membrane binding (77) and highly polar neutral-serine bearing a hydroxyl group at the terminal carbon offers a stronger interaction with the lipid bilayer membranes (78). Other types of PTMs in the residues of NavPA1 sequence may also play roles. It is reported that serine PTMs can occur by diverse mechanisms, including phosphorylation, sulfation, acetylation,
palmitoylation, myristoylation, and glycosylation (79-81). Different PTMs can alter the charge and hydrophobicity (electrostatics), which in turn induce physicochemical properties, structure, and functional changes of the peptide. Ion channel protein arginine methylation and lysine acetylation can enhance current density by increasing the channel cell surface expression (82, 83). A recent paper reported that alanine substitution of polybasic arginine/lysine in Na\textsubscript{v}1.7iPA region in Halo-tagged human full-length Na\textsubscript{v}1.7 does not alter the membrane integration and channel function of Halo-Na\textsubscript{v}1.7 after transfection (84). It would be interesting to test whether combined mutations of polybasic arginine/lysine and multiple adjacent serine or other conserved residues would change the natural full-length Na\textsubscript{v}1.7 polar association that will influence channel function. Additionally, the highly disordered Na\textsubscript{v}iPA1 liberated by engineering from full-length Na\textsubscript{v}1.7 protein likely renders the Na\textsubscript{v}iPA1 different biological properties such as binding to membrane probably via electrostatic interactions and showing an ability for cell nuclear trafficking (12). One possibility that cannot be dismissed is that the nuclear-entry Na\textsubscript{v}iPA1 functions as a transcriptional factor that affects the genes that are critical in regulating Na\textsubscript{v}1.7 functions, reminiscent of the fragmented L-type calcium channel functioning as a transcriptional factor (85, 86). It is also possible that Na\textsubscript{v}iPA1 may function as a decoy peptide that interrupts Na\textsubscript{v}1.7 interactions with partners, since Na\textsubscript{v}iPA1, which is partially aligned to a putative Na\textsubscript{v}1.7 dimerization sequence, may affect channel functions by uncoupling Na\textsubscript{v}1.7 dimerization assembly (87, 88), albeit experimental evidence of such mechanism remains to be shown. The potential signaling pathways that the Na\textsubscript{v}iPA1 affected could be many, since Na\textsubscript{v}1.7 PPI molecule networks involve multiple pathways and Na\textsubscript{v}1.7 (and other TTXs Na\textsubscript{vs}) intracellular segments serve as essential interfaces for many regulatory signaling molecules, including protein-lipids interactions (35, 36). Alterations
of these molecules following nerve injury are essential for ectopic PSN hyperactivity and pain.

Future work will address these questions.
Materials and methods

Sex as a biological variable: Since sex differences exist in experimental and clinical pain and in the responsivity to interventions (52), pain hypersensitivity after TNI and pain reversal responses to treatment were examined in both male and female rats for this study. All Materials and Methods are presented in the Supplemental Methods.

Statistics. Statistical analysis was performed with GraphPad PRISM 9 (GraphPad Software, San Diego, CA). The methods were detailed in the figure legends and results were reported as the mean and standard error of the mean (SEM). Differences were significant for values at p<0.05. For comparisons between groups, in the pilot in vivo testing of TNI operation at three weeks after AAV intraganglionic injection, the effects of vector injection were characterized by treatment area under the curve (tAUC) analysis; in the treatment protocol of established pain, the measures immediately before AAV injection at the 14th day post TNI were used as the tBL for calculating tAUC. In the treatment of established male TNI pain, the data points in one rat who died on the second day after treatment AAV injection (no diagnostic report and likely due to surgical injury) were excluded from the analysis.

Study approval. All animal experiments were performed with the approval of the Medical College of Wisconsin Institutional Animal Care and Use Committee (AUA00007371) in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. The uses of AAV and human iPSC sensory neurons were approved by the Medical College of Wisconsin Institutional Biosafety Committee, with approval numbers IBC20140322 and IBC20220103.
**Author contributions**

HY designed the study and wrote the manuscript. HY, QHH, and TRC reviewed and revised the manuscript. SMS, BIZ, FF, YCX, CSQ, and HY performed experiments, analyzed data, and organized all figures. QHH supervised DRG injection. HY and QHH obtained funding. TRC provided HEK1.7 stable cell line and consulted EP experiments. All authors approved the final version.

**Supplemental material**

View supplemental data

**Data availability**

The raw data, analytic methods, and study materials are described in full in Supplemental Methods. Values for all data points in graphs of the manuscript and supplemental materials are reported in the Supporting Value Data XLS file. All gel data and immunoblots in this study are reported in Full unedited Gel and Western Images PDF file with full annotations. Data for the manuscript and supplemental materials including plasmid nucleotide sequences (text) of pAAV-CBA-GFPNaviPA1 and pCMV-cDNA3.1(+) -hSCN10A-FurinP2A-hSCN2B with annotations of key components of the constructs are findable for the research community through Dataverse (https://dataverse.org) by searching the title of the manuscript or identifier MCWHY.

**Acknowledgments**

This research was supported by grants from 2021 (Catalyst) and 2023 (Transformational) awards from Dr. Ralph and Marian Falk Medical Research Trust, Bank of America, Private Bank (HY
and QHH); National Institutes of Health grant R33NS116203 (HY and QHH) and R21NS137014-01 (Yu); MCW Therapeutic Accelerator Program (2022) (HY); and 2022 and 2023 Advancing a Healthier Wisconsin Endowment Project (5520680 and 5520739) (HY). The authors thank Dr. Kevin Boggs, Director of Technology Development, MCW for providing IP protection of NaviPAs and Dr. Wai-Meng Kwok, MCW for consulting EP techniques. We would also like to thank Mahmudur Rahman and Uarda Gani for lab assistance and to acknowledge Anatomic for providing the hiPSC-SNs.
References


**Figure 1. In silico prediction of Na\(_{V}1.7-\)IDRs and design of candidate Na\(_{V}1.7\)iPAs (1.7iPAs).**

Diagram of rat Na\(_{V}1.7\) protein, with white boxes labeling DI-DIV of Na\(_{V}1.7\) (A) and the red bars below showing position of the predicted iPAs (B). Consensus prediction of IDRs by DEPICTER (C). The phosphorylation sites were predicted by DEPP (D). Nine candidate iPAs with their aa sequences, position in Na\(_{V}1.7\), and IDR scores (E). A map showing each component of an AAV plasmid coding GFP-iPA, a black line pointing to iPAs (F). The structure analysis of GFP-fused 1.7iPA1 by I-TASSER, top panel: structure of free 1.7iPA1 (G). Images (GFP, left; phase, middle; and merged pictures, right) show expression of constructs carrying 1.7iPA1-4 and 6 after transfection to HEK cells (H). Scale bar: 25µm for all. GFP and Gapdh western blots of the cell
lysates after transfection with 1.7iPA1-4 and 6 to HEK cells (I). Initial screening of nine iPAs on $I_{\text{Na}}$ by whole-cell patch-clamp recording as described in Methods after transfection into HEK1.7 cells. * and *** denote $p<0.05$ and 0.001, respectively; one-way ANOVA and Tucky post hoc (J).

**Figure 2. Confirmation of $I_{\text{Na1.7}}$ inhibition by 1.7iPA1, 4, and 6 and gating kinetics.** (A) Representative traces of $I_{\text{Na1.7}}$ by whole-cell patch-clamp recording from naive (transfection without plasmid), GFP, 1.7iPA3 (NP), 1.7iPA1, 1.7iPA4, and 1.7iPA6 transfected HEK1.7 cells. Inserts: recording protocol and current/time scales. Summary of the confirmation tests of candidate
iPAs expression in HEK1.7 cells in (B) comparison of corresponding mean peak current density-voltage (I/V) relationship from different constructs as indicated and (C) quantitative analysis of averaged peak $I_{\text{Na}1.7}$ density; ***p<0.001, one-way ANOVA and Tukey post hoc. No effects of expression of GFPiPA1, GFPiPA4, and GFPiPA6 were observed on steady-state activation (D, inset: $V_{1/2}$ activation) and fast inactivation (E, inset: $V_{1/2}$ inactivation), compared to naive and GFP or NP-transfected HEK1.7 cells. Nav1PA1 is highly conserved in rat, mouse, and human (F). Black and yellow asterisks at the bottom denote positively and negatively charged aa; the red and blue asterisks on the top denote known lysine acetylation and serine phosphorylation sites, and IDR scores and % of positively (+) and negatively (-) charged aa were shown at the right sides of the alignment.
Figure 3. Sodium channel specificity of NaviPA1 (1.7iPA1) inhibition. The aa sequence alignment of 1.7iPA1 with the corresponding sequences of TTXs Nav1.6, Nav1.3, Nav1.1 (A), as well as TTXr Nav1.5, Nav1.8, and Nav1.9 (B) of rat proteins. The homologous aa (identity and similarity) was highlighted in heavy or light black shadows and % of identical or similar aa shown at the right sides of the alignments. (C-G) Panels from left to right show the comparisons of I_{Na} traces in presence of 1.7iPA1 in HEK1.1, 1.3, 1.6, 1.5, and 1.8 cells (insert: pulse protocol and
scale); peak $I_{\text{Na}}$ density (** and *** denote $p<0.01$ and 0.001, one-way ANOVA and Turkey post hoc), $I/V$ curves, steady-state activation (insert: $V_{1/2}$ activation) and fast inactivation kinetics (insert: $V_{1/2}$ inactivation).

Figure 4. $\text{Na}_i\text{PA1}$ on $I_{\text{Na}}$ of rat DRG neurons (male) and hiPSC-SNs (female). (A-C) Panels from top to bottom illustrate representative traces and averaged peak $I_{\text{Na}}$ densities of total $I_{\text{Na}}$ (A),
TTXs $I_{\text{Na}}$ (B), and TTXr $I_{\text{Na}}$ (C) recorded from sensory neurons (diameter $\leq 35 \mu m$) dissociated from naïve male rats subjected with (panels from left to right) sham (surgical exposure without injection), and 4wk after L4/L5 DRG injected with AAV6-encoded GFP, GFPNP, and GFPNavPA1. Inserts: representative PSN images (scale bars $25 \mu m$ for all) of each group, current/time scales, and recording pulse protocol. (D, E) Representative montage ICC images illustrate hiPSC-SNs at DIV25 after transduction with LV-GFPNP (D) and LV-GFPNavPA1 (E) at equal MOI=5. (F-H) illustrate representative traces and averaged peak $I_{\text{Na}}$ densities of total $I_{\text{Na}}$ (F), TTXs $I_{\text{Na}}$ (G), and TTXr $I_{\text{Na}}$ (H) recorded from hiPSC-SNs (DIV25) of sham, expressing NP and NavPA1. Inserts: current/time scales and recording pulse protocol. *, **, and *** denote $p<0.05$, 0.01, and $p<0.001$, one-way ANOVA and Turkey post hoc.
Figure 5. NavIPA1 binds to full-length Nav1.7 protein and phosphoinositides. (A) Immunoblots (IB) show selectivity of Nav1.7 antibody using cell lysates from naïve HEK cells, and HEK1.5, HEK1.7, HEK1.6, HEK1.1, HEK1.3, HEK1.8 cells, and 50B11 cells. (B-E) Representative IHC images show Nav1.7 detection (red) in SDH (red), sciatic nerve (green), DRG neurons (red), and cutaneous nerve fibers (red). Scale bars: 100 µm. (F) IBs of Nav1.7, GFP, NKA1α, Gapdh in the cytosol and membrane samples extracted from HEK1.7 cells transfected with sham (transfection without plasmid), GFP, GFPNavIPA1, and GFP1.7iPA2. A vertical white line in GFP panel denotes that the lanes were run on the same gel but were noncontiguous. (G) Nav1.7 IB (left) and silver stain (right) of inputs (cell lysates, 20 µg for each lane) and pulldown beads (100 L for each lane) prepared by a ‘non-denaturing’ lysis buffer from HEK1.7 cells transfected with GFP, GFPNavIPA1, and GFP1.7iPA2. (G, right panel) Stained gel pieces ranging 100-300 kDa (G, red asterisk denotes Nav1.7 site) from GFPNP and GFPNavIPA1 excised for mass spectrometry. Silver stain on 1D SDS-PAGE gel of GFP-affinity pulldown beads in the
NG108-15 cells transfected with GFPNavPA1 and GFP and cell lysates prepared using denaturing RIPA buffer (H) and the results of PIP strip analysis (I).

Figure 6. Define polybasic NLS and adjacent serine in NavPA1. (A) Sequence alignments of NavPA1, mutant 1 (mt) with alanine substitution of ten serine residues, mt2 by alanine substitution of arginine/lysine (R/K) (mt2) within predicted NLS domain, and mt3-6 with alanine substitution of bi- or tri-serine residues at different serine sites, as indicated. (B-E) ICC comparison
of GFP signals 48 hours after plasmids coding NaviPA1, GFPNP, mt1, and mt2 transfected into HEK1.7 cells. (F) Representative immunoblots of endogenous Nav1.7, as well as GFPNP, NaviPA1, mt1, and mt2, in extracted cytosol, membrane, and nuclear samples after transfection into HEK1.7 cells. Cytosol, membrane, and nuclear loading were indicated by GAPDH, NKA1α, and LamB1, respectively. (F1) Quantitative (ImageJ gel analysis) comparison of membrane binding and nuclear entry of NaviPA1, mt1, and mt2 after transfection, * and ** denote p<0.05 and 0.01, one-way ANOVA and Tucky post hoc. (G) Representative I\(_{Na1.7}\) traces of HEK1.7 cells recorded from sham, GFPNP, NaviPA1, mt1-mt6 (3-4 days after transfection), as indicated. (H) Quantification summary of peak I\(_{Na}\) densities; *, **, and *** denote p<0.05, <0.01, and <0.001; one-way ANOVA and Tukey post hoc.
Figure 7. Treatment of established neuropathic pain by DRG AAV6-NaviPA1 (male rats).

Purified AAVs (A, silver stain. A vertical white line denotes that the lanes were run on the same gel but were noncontiguous) were prepared for the experiment in an animal protocol schematically outlined (B). The time courses (C-F) of vF, Pin, Heat, and Cold before and after DRG injection of either AAV6-NaviPA1 (n=7) or AAV6-NP (control, n=8). The measures on the 14th day after TNI and before AAV treatment (tBL) were converted as the peak pain intensity (100%), and the measures of each sensory modality after treatment were normalized to the measures at the tBL and the percentage of pain relief for each modality at multiple time points was calculated (C1-F1).
*p<0.05, **p<0.01 and ***p<0.001 for comparisons to the tBL within group and #p<0.05, ##p<0.01, and ###p<0.001 between groups. Repeated measures two-way ANOVA for vF and Heat, and Tukey (within group) and Bonferroni (between groups) post hoc; and non-parametric Friedman ANOVA for Pin and Cold tests and Dunn’s post hoc. Summed average pain relief in the 6-week treatment course showed 52%, 49%, 69%, and 67% reduction of vF-, Pin-, Cold-, and Heat-stimulated mechanical and thermal pain behaviors, respectively (G). ** p<0.01 *** p<0.001, unpaired, two-tailed student’s t-test. (H) Results of CPP scores (seconds, s) of pre-conditioning chamber and of the GBP-paired chamber between AAV-NavlPA1 (n=7) and AAV-NP (control, n=8), ***p<0.001 (unpaired, two-tailed Student’s t-test)
Figure 8. IHC of GFP-NaviPA1 and target gene expression. (A-D) Representative IHC montage images (GFPNaviPA1 with Tubb3) show neuronal expression profile 6 weeks after AAV-NaviPA1 injection in TNI rats (A), colocalization of GFP-NaviPA1 with Na\textsubscript{v}1.7 and Na\textsubscript{v}1.6 positive neurons (B, C), but not with GFAP positive perineuronal glia (D, the square region was enlarged and montage images shown as D1). (E-G) Representative IHC montage images illustrate GFPNaviPA1 (green) and Na\textsubscript{v}1.7 (red) in PSN central terminals of ipsilateral spinal dorsal horn
(E), GFPNAviPA1 (green) and Tubb3 (red) in sciatic nerve (F), and GFPNAviPA1 (green) and NF200 (red) in PSN peripheral terminals of skin section (G). Scale bar (µm): A, 200; B, C, D and D1, 100; E, 200; G and G, 50µm.

Figure 9. NaviPA1 expression on neuronal excitability of rat PSNs (male). (A, B) Representative AP traces elicited by 250 ms depolarizing current of 180 pA (A) and 280 pA (B) (same cells) from RMP were recorded from DRG neurons dissociated from the rats of sham, TNI only, and GFP-expressing neurons in TNI treated with AAV6-NP or AAV6-NaviPA1, as indicated.
(C) Comparison of responses (number of APs evoked by a 250ms stimulus) for the populations of DRG neurons in different groups across a range of step current injections from 100 to 280 pA; ***p < 0.001, two-way ANOVA of main effects of groups with Bonferroni post-hoc. Scatter plots with bars show analysis of the rheobases (D) and AP numbers evoked by input current at 180 pA (E) and 280 pA (F) from RMP, respectively. The number in each group is the number of analyzed neurons per group. * and *** denote p<0.05 and <0.001, respectively, One-way ANOVA and Turkey post-hoc.
Figure 10. Analgesia of DRG-AAV6-Nav1PA1 treatment in female TNI rats. Analogous figures to Fig. 7 show significant analgesia (A-D) and % of pain reduction (A1-D1) after DRG delivery of AAV6-Nav1PA1 in the established TNI pain behaviors of female rats. *, **, and *** denote $p<0.05$, 0.01, and 0.001 for comparisons to the treatment baseline (tBL) within group and #p<0.05, ##p<0.01, and ###p<0.001 for comparisons between groups. Repeated measures parametric two-way ANOVA for vF and Heat followed by Tukey (within group) and Bonferroni (between groups) post hoc; and non-parametric Friedman ANOVA for Pin and Cold tests and Dunn’s post hoc. Right panels of A2-D2 show average pain relief of each modality in 3.5-month treatment, ** $p<0.01$ and *** $p<0.001$ comparisons between groups (unpaired, two-tailed Student’s t tests). CPP difference scores (s) of pre-conditioning chamber and of the GBP-paired
chamber between AAV-Nav1PA1 (n=8) and AAV-NP (control, n=8), *p<0.01 (unpaired, two-tailed Student’s t test) (E). Representative montage IHC images colocalization of GFP-Nav1PA1 with Tubb3 (F), Nav1.7 (G), and Nav1.6 (H) 6 weeks after AAV-Nav1PA1 injection. Scale bar: 100 m for F-H.

**Table 1.** Unique hNav1.7 peptides (red) detected in GFPNav1PA1 pull-down samples

<table>
<thead>
<tr>
<th>Annotated Sequence</th>
<th>Positions in Master Proteins</th>
<th>Peak found in Nav1PA1</th>
<th>Peak found in NP</th>
<th>Abundance Ratio: Nav1PA1/NP</th>
</tr>
</thead>
<tbody>
<tr>
<td>[K].KDDDEEAPKSSDLEAGK.[Q]</td>
<td>Q15858 [40-57]</td>
<td>High</td>
<td>Peak found</td>
<td>3.595</td>
</tr>
<tr>
<td>[R].DIGSETEFADEHSIFGDNESR.[R]</td>
<td>Q15858 [563-584]</td>
<td>High</td>
<td>Not Found</td>
<td>100</td>
</tr>
<tr>
<td>[K].VSYEPITTLK.[R]</td>
<td>Q15858 [1875-1885]</td>
<td>High</td>
<td>Not Found</td>
<td>100</td>
</tr>
<tr>
<td>[K].INDDCTLPR.[W]</td>
<td>Q15858 [899-907]</td>
<td>found</td>
<td>found</td>
<td>1.68</td>
</tr>
<tr>
<td>[K].YFYYLEGSK.[D]</td>
<td>Q15858 [302-310]</td>
<td>found</td>
<td>found</td>
<td>1.929</td>
</tr>
</tbody>
</table>